Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line

PloS One
Yoshinori TsukumoTakayoshi Suzuki

Abstract

In non-small cell lung cancer (NSCLC), oncogenic driver mutations including those in KRAS and EGFR are typically mutually exclusive. However, recent reports indicate that multiple driver mutations are found in a certain percentage of cancers, and that the therapeutic responses of such cases with co-mutations of driver genes are largely unclear. Here, using CRISPR-Cas9-mediated genome editing, we generated isogenic cell lines harboring one or two copies of an EGFR-activating mutation from the human NSCLC cell line A549, which is known to harbor a homozygous KRAS gene mutation. In comparison with parent cells with KRAS mutation alone, cells with concomitant EGFR mutation exhibited higher sensitivity to EGFR-tyrosine kinase inhibitors (TKIs) but not to conventional anti-cancer drugs. In particular, cells with two copies of EGFR mutation were markedly more sensitive to EGFR-TKIs compared with parent cells. Thus, the presence of concomitant EGFR mutation can affect the TKI response of KRAS-mutated cells, implying that EGFR-TKI may represent an effective treatment option against NSCLC with EGFR/KRAS co-mutation.

References

Aug 15, 2006·The Journal of Clinical Investigation·Jeffrey A EngelmanPasi A Jänne
Nov 8, 2006·Molecular Cancer Therapeutics·Ogechi N IkediobiRichard Wooster
Dec 22, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chen MaoQing Chen
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Jun 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DeardenD Blowers
Oct 26, 2013·Nature Protocols·F Ann RanFeng Zhang
Nov 10, 2013·Nature Medicine·Curtis R Chong, Pasi A Jänne
Jan 21, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jin-Ji YangYi-Long Wu
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Aug 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ReckUNKNOWN ESMO Guidelines Working Group
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Mar 5, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lynette M ShollUNKNOWN LCMC Investigators
Jul 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E RulliUNKNOWN TAILOR trialists
Apr 16, 2016·Scientific Reports·Ting-Wei Will ChiangStephen P Jackson
Apr 19, 2016·Journal of Pathology and Translational Medicine·Taebum LeeSang-Won Um
Aug 3, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vassiliki PapadimitrakopoulouRoy S Herbst
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 13, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nicolas GuibertJulien Mazières
Apr 14, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerMiranda Hughes
Apr 27, 2017·The New England Journal of Medicine·Mariam Jamal-HanjaniUNKNOWN TRACERx Consortium
May 20, 2017·Molecular Cancer Therapeutics·Judith RaimbourgLisenn Lalier
Jun 22, 2018·Science Translational Medicine·Herwig P MollEmilio Casanova
Jun 22, 2018·Science Translational Medicine·Björn KruspigDaniel J Murphy

❮ Previous
Next ❯

Methods Mentioned

BETA
Transfection
PCR
genotyping
electrophoresis

Software Mentioned

Image J

Related Concepts

Related Feeds

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.